Linagliptin treatment in subjects with type 2 diabetes with and without mild‐to‐moderate renal impairment
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: Renal disease is a frequent comorbidity of type 2 diabetes mellitus (T2DM) and an important factor complicating the choice of glucose‐lowering drugs. The aim of this analysis was to evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)‐4 inhibitor linagliptin (5 mg/day) in mono, dual or triple oral glucose‐lowering regimens in subjects with T2DM and mild or moderate renal impairment (RI). Methods: In this pooled analysis of three 24‐week, placebo‐controlled, phase 3 trials, subjects with mild (estimated glomerular filtration rate (eGFR) 60–<90 ml/min/1.73 m 2, n = 838) or moderate RI (30–<60 ml/min/1.73 m 2, n = 93) were compared with subjects with normal renal function (≥90 ml/min/1.73 m 2, n = 1212). Results: Subjects with RI were older, had longer duration of diabetes, and increased prevalence of diabetes‐related comorbidities. After 24 weeks, linagliptin achieved consistent placebo‐corrected mean glycated haemoglobin (HbA1c) changes across the three renal function categories: normal (−0.63%; p < 0.0001), mild RI (−0.67%; p < 0.0001) and moderate RI (−0.53%; p < 0.01), with no inter‐group difference (p = 0.74). Renal function with linagliptin remained stable across all categories. In linagliptin‐treated subjects, overall adverse event (AE) rates and serious AE rates were similar to placebo. The incidence of hypoglycaemia with linagliptin and placebo was 11.1 versus 6.9%, 11.9 versus 9.0% and 15.9 versus 12.0% in the normal, mild RI and moderate RI categories, respectively. Conclusions: This pooled analysis provides evidence that linagliptin is an effective, well‐tolerated and convenient treatment in subjects with T2DM and mild or moderate RI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“Intensive glycaemic control can improve kidney outcomes [8–10].”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 1×
“Intensive glycaemic control can improve kidney outcomes [8–10].”
BackgroundKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Risk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., & for the UKPDS Study Group (2006) · Diabetes · doi:10.2337/db05-1620 · Cited by 927
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes
Plantinga, L. C., Crews, D. C., Coresh, J., Miller, E. R., Saran, R., Yee, J., Hedgeman, E., Pavkov, M., Eberhardt, M. S., Williams, D. E., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07891109 · Cited by 408 · cited 1×
“A similar proportion has been reported in subjects with undiagnosed diabetes [6].”
Background
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
“linagliptin (39), dosage adjustments are required.”
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care · doi:10.2337/dc16-1371 · Cited by 113
“The neutral effect of GLP-1–based therapy on GFR is in accordance with several randomized clinical trials of 12–30 weeks duration, in which DPP-4I or GLP-1RA treatment did not change (the slope of) creatinine-eGFR in patients with type 2 diabetes with (27–30) and without (5,29,31) renal impairment.”
ResultScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
“Linagliptin was generally well tolerated, with an incidence rate of adverse events with linagliptin similar to placebo, even in patients with mild to moderate CKD [78].”
Background
Metadata
- Authors
- Groop, P. ‐., Del Prato, S., Taskinen, M. ‐., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., & Woerle, H. ‐.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-03-24
- Volume
- 16
- Issue
- 6
- Pages
- 560-568
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2001209027
- Cited by
- 51
- References
- 10
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Linagliptin treatment in subjects with type 2 diabetes with and without mild‐to‐moderate renal impairment. https://app.cochat.ai/papers/10.1111/dom.12281
- The paper
- Groop, P. ‐., Del Prato, S., Taskinen, M. ‐., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., & Woerle, H. ‐. (2014). Linagliptin treatment in subjects with type 2 diabetes with and without mild‐to‐moderate renal impairment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.